United States · FDA National Drug Code directory
doxorubicin hydrochloride, Liposomal
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 0338-9581_a4227051-225f-49e2-9e5c-653ea0f99739
- Product NDC
- 0338-9581
- Form
- INJECTION, SUSPENSION, LIPOSOMAL
- Composition / generic term
- doxorubicin hydrochloride
- Labeler
- Baxter Healthcare Corporation
- Marketing category
- UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE
- Marketing start / end (source format)
- 20231219
- Source listing expiry
- 20261231
Source-listed ingredients
- DOXORUBICIN HYDROCHLORIDE — 2 mg/mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 VIAL, SINGLE-USE in 1 CARTON (0338-9581-02) / 10 mL in 1 VIAL, SINGLE-USE (0338-9581-01) · 0338-9581-02
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →